



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/934,250	08/21/2001	Wenbin Dang	GPT-029.01	6514

29755 7590 05/24/2002

FOLEY, HOAG & ELIOT LLP
ONE POST OFFICE SQUARE
BOSTON, MA 02109

EXAMINER

HUI, SAN MING R

ART UNIT	PAPER NUMBER
----------	--------------

1617

DATE MAILED: 05/24/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/934,250

Applicant(s)

DANG ET AL.

Examiner

San-ming Hui

Art Unit

1617

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 28 February 2002.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-56 is/are pending in the application.
- 4a) Of the above claim(s) 42-56 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-41 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 5.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). _____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____.

DETAILED ACTION

Applicant's election with traverse of the invention of Group I, claims 1-41 in Paper No. 7, received February 28, 2002 is acknowledged. The traversal is on the ground(s) that no undue burden should be imposed on the Examiner to search all the inventions encompassed by the claims. This is not found persuasive because the inventions encompassed by the claims in the instant invention are patentably distinct invention. Note that the search fields for method of use employing a composition and that for a composition containing the same ingredients are diverse. The search is not limited to patent files. Therefore, the search for the methods encompassed by the claims presents an undue burden to the Office.

Applicant's election with traverse of the analgesic species, lidocaine HCl and the biocompatible oil specie, sesame oil, in Paper No. 7, received February 28, 2002 is acknowledged. Since the applicant did not state the reason of traversal, it is treated as election without traverse.

The requirement is still deemed proper and is therefore made FINAL.

Claims 42-56 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention.

Claims 1-41 are examined on the merits herein to the extent they read on the elected invention and species.

Claim Objections

Claims 35-38 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim.

Art Unit: 1617

Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. Claims 35-38 are drawn to the same kit containing the active agents herein. Please note that the recitation of "intended use", e.g., treating pain or tinnitus, does not lend patentable weight to composition claims.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 2, 13-18, 21, 23, 28, 29 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 13-18, 21, 23, 28, and 29 recite the limitation "all biocompatible oils" in line 1. There is insufficient antecedent basis for this limitation in the claims.

The term "vegetable oil" in claim 2 renders the claims indefinite as to the vegetable oil encompassed thereby. It is unclear what the metes and bounds in the instant claim are.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

Art Unit: 1617

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-12, 27, 30-33, and 41 are rejected under 35 U.S.C. 102(b) as being anticipated by Lostritto (Journal of Parenteral Science & Technology from the IDS received February 28, 2002).

Lostritto teaches a flowable composition containing sesame oil 30% and lidocaine HCl 1% (See page 221, col. 1, second to last paragraph).

The viscosity properties and the dielectric constant are inherently possessed by the pharmaceutical composition of Lostritto.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 13-26, 28, 29, and 34-40 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lostritto (Journal of Parenteral Science & Technology from the IDS received February 28, 2002) in view of Sonne (US Patent 6,193,985).

Lostritto teaches a flowable composition containing sesame oil 30% and lidocaine HCl 1% (See page 221, col. 1, second to last paragraph).

Lostritto does not expressly teach the amount of lidocaine to be at least 2%, 3% to 80%, 4-67%, at least 10%, or at least 40%. Lostritto does not expressly teach the

Art Unit: 1617

amount of the biocompatible oil to be at least 33%, at least 50%, at least 75%, at least 85%, or at least 95%. Lostritto does not expressly teach the solvent amount no more than 10%. Lostritto does not expressly teach the composition herein can be incorporated into a kit containing the composition herein and instructions for combining the agents herein.

Sonne teaches a composition containing up to lidocaine and sesame oil as a solvent (See particularly col. 5, line 33; also col. 6, line 51). Sonne also teaches that the composition may be optimized with respect to bioadhesion, sprayability and viscosity as desired (See particularly col. 6, line 47-50).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to employ the herein claimed amount of lidocaine, solvent, and sesame oil in a composition. It would have been obvious to one of ordinary skill in the art at the time the invention was made to incorporate the herein claimed composition and instructions and combine these agents into a kit.

Possessing the cited prior art teaching, one of ordinary skill in the art would have been motivated to employ the herein claimed amount of lidocaine, solvent, and sesame oil into a composition because optimization of therapeutic effect parameters (e.g., amount of the actives) is obvious as being within the skill of the artisan. One of ordinary skill in the art would have been motivated to incorporate the composition herein and instructions for combining the agents into a kit: putting the claimed compositions (lidocaine and sesame oil) together in a kit would be obvious as being within the purview of the artisan. In addition, the inclusion of instructions on how to use a

Art Unit: 1617

pharmaceutical product, regardless what the indication might be, is mandated by 21 CFR 201.57 and, thus, obvious to one of ordinary skill in the art. Mere inclusion of a specific instruction document with the composition in a kit will not render additional patentable weight to claims drawn to composition kit.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to San-ming Hui whose telephone number is (703) 305-1002. The examiner can normally be reached on Mon 9:00 to 1:00, Tu - Fri from 9:00 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Minna Moezie, J.D., can be reached on (703) 308-4612. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4556 for regular communications and (703) 308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

San-ming Hui
May 20, 2002

RUSSELL TRAVERS
PRIMARY EXAMINER
GROUP 1200